ARPA-H Inaugural Director Dr. Renee Wegrzyn at 18th Non-Dilutive Funding Summit (2023) скачать в хорошем качестве

ARPA-H Inaugural Director Dr. Renee Wegrzyn at 18th Non-Dilutive Funding Summit (2023)

WHAT IS ARPA-H? Some breakthrough ideas don’t get enough attention because they’re too high-risk, high-cost, or long-term, because they don’t fit well into academia or the commercial sector, or because they require complex collaborations. ARPA-H aims to support promising opportunities which concern health but which fall in that gap. ARPA-H will have only extramural labs, and it will facilitate research directed at solving practical problems. ARPA-H is designed to be the DARPA of human health. Find out more about ARPA-H: https://freemindgroup.com/2022/03/16/... MEET DR. RENEE WEGRZYN, 1ST DIRECTOR OF NEWLY FORMED ARPA-H Dr. Renee Wegrzyn is the inaugural director of ARPA-H. She brings to her post a distinguished record of service to the public and of achievement in the private sector. Prior to Dr. Wegrzyn’s appointment by President Biden, she worked in the private sector as the Vice President of Business Development at Ginko Bioworks. There she worked on applications of synthetic biology to outpacing infectious diseases. Earlier, she served as Program Manager with a $250 million portfolio in the Biological Technologies Office of the Defense Advanced Research Projects Agency (DARPA)—the organizational paradigm for the Advanced Research Projects Agency for Health. She also served as a technical advisor to the Intelligence Advanced Research Projects Activity (IARPA). At DARPA, Wegrzyn leveraged the tools of synthetic biology and gene editing to enhance biosecurity, support the domestic bioeconomy, and thwart biothreats. Wegrzyn received the Superior Public Service Medal for her work and contributions at DARPA. Dr. Wegrzyn has also served as a Senior Advisor to the Nuclear Threat Initiative and as a member of the scientific advisory board for the National Academies Standing Committee on Biotechnology Capabilities and National Security Needs, and worked as the Senior Lead Technologist at Booz Allen Hamilton and the Leader of the Assay Development Group at Adlyfe, where her work included biosecurity and gene therapy. She earned her BSc and PhD in Applied Biology from Georgia Tech, conducted post-doctoral research at the Center for Molecular Biology of Heidelberg University, and served as a fellow at the Center for Health Security Emerging Leaders in Biosecurity in the Bloomberg Schoolf of Public Health at the Johns Hopkins University. FREEMIND Founded in 1999, the FreeMind Group helps life science companies secure non-dilutive funding to fund R&D. Every year FreeMind garners over $100 million for its clients, with awards ranging from hundred-thousand dollar grants to multi-million dollar programs. Funding sources include NIH, DOD, BARDA, NSF, FDA, etc., as well as private foundations. Learn more here: https://freemindgroup.com/about-us/. You may find our LinkedIn page useful, as we regularly post news about non-dilutive funding opportunities, announcements about conferences with the best partnering for life science professionals, and discounts for those conferences. Connect with us here:   / freemind-group  . We hope you gain useful information from these recordings of the 18th Non-Dilutive Funding Summit.